Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Andrew J. Carroll"'
Autor:
Mignon L. Loh, Alison M. Friedmann, David T. Marshall, Nyla A. Heerema, Leonard A. Mattano, Naomi J. Winick, Cindy Wang, Julie M. Gastier-Foster, William L. Carroll, Meenakshi Devidas, Kelly W. Maloney, Andrew J. Carroll, Stephen P. Hunger, Nina S. Kadan-Lottick, Patrick J. Buckley, Michael J. Borowitz, Brent L. Wood, Yousif Matloub, Elizabeth A. Raetz, Linda C. Stork
Publikováno v:
Journal of Clinical Oncology. 39:1540-1552
PURPOSE Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with standard-risk B-acu
Autor:
Kimberly P. Dunsmore, Julie M. Gastier-Foster, Nancy Eisenberg, Kirk R. Schultz, Patrick A. Zweidler-McKay, William L. Carroll, Barbara L. Asselin, Nikki Briegel, Nyla A. Heerema, Mignon L. Loh, Natia Esiashvili, Robert J. Hayashi, Stephen P. Hunger, Andrew J. Carroll, Naomi J. Winick, Karen R. Rabin, Meenakshi Devidas, Elizabeth A. Raetz, Brent L. Wood, Stuart S. Winter, Zhiguo Chen
Publikováno v:
J Clin Oncol
PURPOSE Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease. PATIENTS AND METHODS From 2007 to 2014,
Autor:
William L. Carroll, Julie M. Gastier-Foster, Nina S. Kadan-Lottick, Patrick J. Buckley, Michael J. Borowitz, Kelly W. Maloney, Elizabeth A. Raetz, Stephen P. Hunger, Linda C. Stork, Alison M. Friedmann, Cindy Wang, Meenakshi Devidas, David T. Marshall, Brent L. Wood, Andrew J. Carroll, Yousif Matloub, Mignon L. Loh, Naomi J. Winick, Nyla A. Heerema, Leonard A. Mattano
Publikováno v:
J Clin Oncol
PURPOSE Children’s Oncology Group (COG) AALL0331 tested whether intensified postinduction therapy that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL) would also improve outcomes for those with standard-risk (
Autor:
Thai Hoa Tran, Shalini Reshmi, Ilan Richard Kirsch, John A. Kairalla, Sarah K Tasian, Kirk R. Schultz, Elizabeth A. Raetz, Mary Shago, Andrew J. Carroll, Meenakshi Devidas, Stephen Hunger, Mignon L. Loh, Lewis B. Silverman
Publikováno v:
Journal of Clinical Oncology. 40:10023-10023
10023 Background: Minimal residual disease (MRD) assessment by immunoglobulin/T-cell receptor (Ig/TCR) polymerase chain reaction (PCR) is currently being used in the international pediatric Philadelphia chromosome-positive acute lymphoblastic leukemi
Autor:
Mignon L. Loh, Nyla A. Heerema, Eric Larsen, Naomi J. Winick, Heng Xu, Meenakshi Devidas, Elaine R. Mardis, Mary V. Relling, Takaya Moriyama, Elizabeth A. Raetz, Yunfeng Dai, Gerard P. Zambetti, Paul L. Martin, Ching-Hon Pui, Cheng Cheng, William E. Evans, Wenjian Yang, Kim E. Nichols, Brent L. Wood, W. Paul Bowman, Andrew J. Carroll, William L. Carroll, Julie M. Gastier-Foster, Xueyuan Cao, Maoxiang Qian, Stephen P. Hunger, Charles G. Mullighan, Robert S. Fulton, Michael J. Borowitz, Hui Zhang, Jun J. Yang
Publikováno v:
Journal of Clinical Oncology. 36:591-599
Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this t
Autor:
Nyla A. Heerema, Eric Larsen, William L. Carroll, Wanda L. Salzer, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Joanne M. Hilden, Naomi J. Winick, Michael J. Burke, Brent L. Wood, Lia Gore, Yunfeng Dai, Michael J. Borowitz, Andrew J. Carroll, Meenakshi Devidas
Publikováno v:
Journal of Clinical Oncology. 39:10004-10004
10004 Background: Children and young adults with very high risk (VHR) B-acute lymphoblastic leukemia (B-ALL) [13-30 years of age with any features or 1-30 years of age with adverse prognostic features including KMT2A rearrangements, iAMP21, hypodiplo
Autor:
Gabriela Gheorghe, Nyla A. Heerema, No'eau Simeona, Amanda McCaustland, Andrew J. Carroll, Brent L. Wood, Bridget S. Wilson, Stuart S. Winter
Publikováno v:
Journal of Clinical Oncology. 39:e19006-e19006
e19006 Background: The surface expression of mature B-cell markers have led to the development of immunotherapies against B-lineage lymphoblastic leukemia/lymphoma (B-ALL/B-LLy). Relapsing clones that have altered surface antigen expression are commo
Autor:
Andrew J. Carroll, Patrick A. Zweidler-McKay, William L. Carroll, Nyla A. Heerema, Karen R. Rabin, Mignon L. Loh, Natia Esiashvili, Meenakshi Devidas, Stephen P. Hunger, Naomi J. Winick, David T. Teachey, Nathan Gossai, Kimberly P. Dunsmore, Brent L. Wood, Stuart S. Winter, Elizabeth A. Raetz, Michael J. Burke, Zhiguo Chen
Publikováno v:
Journal of Clinical Oncology. 39:10003-10003
10003 Background: In B-acute lymphoblastic leukemia (B-ALL), CNS2 was associated with inferior 5-year (yr) event-free and overall survival (EFS/OS) in recent trials. Here, we report the impact of CNS2 in T-ALL on AALL0434 and AALL1231, recently compl
Autor:
Elizabeth A. Raetz, Nyla A. Heerema, Leonard A. Mattano, Stephen P. Hunger, Eric Larsen, Brent L. Wood, Mignon L. Loh, Naomi J. Winick, Julie M. Gastier-Foster, Kelly W. Maloney, Meenakshi Devidas, Andrew J. Carroll, William L. Carroll, Michael J. Borowitz, Si Chen, Cheryl L. Willman
Publikováno v:
Journal of Clinical Oncology. 35:2527-2534
Purpose To determine the prognostic significance of blasts, and of white and red blood cells, in CSF samples at diagnosis of acute lymphoblastic leukemia (ALL), a uniform CSF and risk group classification schema was incorporated into Children’s Onc
Autor:
Karen R. Rabin, Michael J. Borowitz, Mignon L. Loh, Naomi J. Winick, Zhiguo Chen, Brent L. Wood, Wanda L. Salzer, Andrew J. Carroll, Kelly W. Maloney, Stephen P. Hunger, Nyla A. Heerema, Eric Larsen, Elizabeth A. Raetz, Anne L. Angiolillo, Michael J. Burke, Johann K. Hitzler, William L. Carroll, Reuven J. Schore, Meenakshi Devidas
Publikováno v:
Journal of Clinical Oncology. 38:10510-10510
10510 Background: Patients with DS and B-ALL experience increased rates of relapse and toxicities. Here, we report results from 4 COG trials (2003-2018). Methods: We analyzed clinical, and outcome data for DS (n = 743) and non-DS (n = 21,703) patient